Abstract Background and Aim As far as research regarding any disease is concerned, each
and every aspect poses a challenge. One such entity that poses a challenge in our arena is
oral submucous fibrosis (OSF) as no effective treatment is available for this progressively
disabling condition with high malignant potential. Hence the present study was undertaken
with the aim to determine the use of pentoxifylline (PTX) on the clinical and histopathologic
course of OSF. Method Thirty clinically confirmed OSF patients were categorized randomly …

Sir, In the presented study by Patil and Maheshwari [1] on the efficacy of pentoxifylline in the
management of oral submucous fibrosis, it is clearly concluded that the patients in their
study were benefited by administration of 400 mg pentoxifylline twice daily for a period three
months. The control group in their study was administered multivitamins, the composition of
which not mentioned in their study, which by itself could possibly have some benefits in oral
submucous fibrosis patients.[2] If the methodology of their study could have included the …